US 12,226,412 B2
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
Hazel Hunt, Storrington (GB); Tony Johnson, Harlow (GB); Nicholas Ray, Harlow (GB); and Iain Walters, Nottingham (GB)
Assigned to Corcept Therapeutics, Inc., Redwood City, CA (US)
Filed by Corcept Therapeutics, Inc., Menlo Park, CA (US)
Filed on Mar. 15, 2023, as Appl. No. 18/121,694.
Application 15/013,218 is a division of application No. 14/487,347, filed on Sep. 16, 2014, granted, now 9,273,047, issued on Mar. 1, 2016.
Application 14/487,347 is a division of application No. 13/901,946, filed on May 24, 2013, granted, now 8,859,774, issued on Oct. 14, 2014.
Application 18/121,694 is a continuation of application No. 17/387,881, filed on Jul. 28, 2021, granted, now 11,648,245.
Application 17/387,881 is a continuation of application No. 17/146,735, filed on Jan. 12, 2021, granted, now 11,576,907, issued on Feb. 14, 2023.
Application 17/146,735 is a continuation of application No. 16/570,839, filed on Sep. 13, 2019, granted, now 10,973,813, issued on Apr. 13, 2021.
Application 16/570,839 is a continuation of application No. 15/889,494, filed on Feb. 6, 2018, granted, now 10,456,392, issued on Oct. 29, 2019.
Application 15/889,494 is a continuation of application No. 15/621,013, filed on Jun. 13, 2017, granted, now 9,956,216, issued on May 1, 2018.
Application 15/621,013 is a continuation of application No. 15/013,218, filed on Feb. 2, 2016, granted, now 9,707,223, issued on Jul. 18, 2017.
Claims priority of provisional application 61/781,269, filed on Mar. 14, 2013.
Claims priority of provisional application 61/759,520, filed on Feb. 1, 2013.
Claims priority of provisional application 61/715,907, filed on Oct. 19, 2012.
Claims priority of provisional application 61/691,083, filed on Aug. 20, 2012.
Claims priority of provisional application 61/651,669, filed on May 25, 2012.
Prior Publication US 2023/0330084 A1, Oct. 19, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4745 (2006.01); A61K 31/497 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/5383 (2006.01); A61K 31/56 (2006.01); A61K 45/06 (2006.01); C07D 471/04 (2006.01); C07D 498/04 (2006.01); C07D 519/00 (2006.01)
CPC A61K 31/4745 (2013.01) [A61K 31/497 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/5383 (2013.01); A61K 31/56 (2013.01); A61K 45/06 (2013.01); C07D 471/04 (2013.01); C07D 498/04 (2013.01); C07D 519/00 (2013.01)] 8 Claims
 
1. A method of treating a disorder selected from hyperglycemia, diabetes, cardiovascular disease, hypertension, depression, major psychotic depression, and Alzheimer's disease, the method comprising administering to a subject in need thereof, a therapeutically effective amount of a glucocorticoid receptor modulator (GRM) compound, thereby treating the subject suffering from, or suspected of suffering from, hyperglycemia, diabetes, cardiovascular disease, hypertension, depression, major psychotic depression, or Alzheimer's disease, wherein said GRM compound is selected from
(R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4.4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridine-2-yl)methanone, having the formula:

OG Complex Work Unit Chemistry
(R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4,4a, 5,6,7,8-hexahydro-1-H-pyrazolo[3,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone, having the formula:

OG Complex Work Unit Chemistry
and pharmaceutically acceptable salts thereof; and
(R)-(1-(4-fluorophenyl)-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone, having the formula

OG Complex Work Unit Chemistry